Opinion|Videos|December 4, 2024
The Clinical and Economic Impact of LEMS in SCLC Care
Author(s)Wade Iams, MD
Key Takeaways
- Disparities in healthcare access can lead to delayed diagnosis and suboptimal treatment of LEMS in small cell lung cancer patients, affecting outcomes.
- Quantifying the economic burden of LEMS requires evaluating direct medical costs, indirect costs, and patient out-of-pocket expenses.
A medical expert discusses how disparities in health care access affect the management and outcomes of Lambert-Eaton myasthenic syndrome (LEMS) in patients with small cell lung cancer, how health care providers can quantify the economic burden of LEMS on both patients and health care systems, the role of patient-reported outcomes in providing deeper insights into the clinical and economic burden of LEMS, and how health systems can utilize real-world data to better understand the indirect costs of LEMS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do disparities in health care access affect the management and outcomes of Lambert-Eaton myasthenic syndrome (LEMS) in patients with small cell lung cancer?
- How can health care providers quantify the economic burden of LEMS on both patients and health care systems?
- In what ways can patient-reported outcomes provide deeper insights into the clinical and economic burden of LEMS?
- How can health systems utilize real-world data to better understand the indirect costs of LEMS?
Advertisement
Related to this article
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
Medicare Advantage plans have varied motivations, strategies, and aspirations for addressing health-related social needs among home health beneficiaries, highlighting a need to expand the scope of supplemental benefits.
2026 Nobel Prize in Medicine honors optogenetics pioneers who turn algae light-sensing protein into neural switches, transforming brain mapping and enabling vision-restoration trials.
Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals potentially receiving the highest reconciliation payments.
A comparison of 2013 and 2022 data shows that cancer costs are not uniformly rising. Costs decreased for metastatic colorectal cancer but increased for both metastatic non–small cell lung cancer and multiple myeloma.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
4
FDA Approves First Heart Valve to Keep Pace With Children's Growth
5